GHRP-2

Research literature consistently reports a short half-life for GHRP-2, often cited around 30 minutes in humans, necessitating multiple daily administrations for sustained effect.

Due to its short half-life, multiple daily administrations are commonly discussed in research protocols to maintain elevated GH pulses. Administration on an empty stomach is often suggested to maximize GH release and minimize potential attenuation by circulating fatty acids or glucose.

• Mod GRF 1-29 (CJC-1295 without DAC)

  When co-administered, GHRP-2 and Mod GRF 1-29 (or other GHRH analogs) stimulate GH release through distinct mechanisms, leading to a synergistic increase in pulsatile GH secretion that is significantly greater than either peptide alone.

  Synergistic

• CJC-1295 with DAC

  Similar to Mod GRF 1-29, co-administration with CJC-1295 with DAC (which provides a prolonged GHRH signal) can lead to enhanced and sustained GH release when combined with GHRP-2's pulsatile stimulation.

  Synergistic

• Somatostatin (Growth Hormone Inhibiting Hormone)

  Somatostatin inhibits GH release. While GHRP-2 can overcome some somatostatin inhibition, excessively high somatostatin levels may attenuate GHRP-2's effects. GHRP-2 itself can suppress endogenous somatostatin.

  Use Caution

• High glucose or fatty acid levels

  Research suggests that elevated blood glucose or free fatty acid levels can blunt the GH response to GHRPs. Therefore, administration on an empty stomach is commonly discussed to maximize efficacy.

  Use Caution

• Corticosteroids

  Chronic use of high-dose corticosteroids can suppress GH secretion and may potentially reduce the effectiveness of GHRP-2. Monitoring of GH response is advised.

  Use Caution

• Insulin

  Insulin and GH have opposing effects on glucose metabolism. While GHRP-2 indirectly increases GH, which can transiently increase insulin resistance, careful monitoring of blood glucose is prudent when combining with insulin, especially in susceptible individuals.

  Monitor Combination

1. 1Gather materials: lyophilized GHRP-2 vial, bacteriostatic water for injection (BWFI), sterile syringe, alcohol wipes.
2. 2Remove the cap from the GHRP-2 vial and wipe the rubber stopper with an alcohol wipe.
3. 3Draw the desired amount of BWFI into the sterile syringe (e.g., 1mL per 5mg vial for a common concentration).
4. 4Slowly inject the BWFI into the GHRP-2 vial, aiming the stream at the side of the vial to avoid direct forceful contact with the peptide powder.
5. 5Do not shake the vial. Gently swirl the vial to facilitate dissolution of the peptide. If necessary, allow it to sit in a refrigerator for a short period to fully dissolve.
6. 6Once fully dissolved, the solution should be clear. Store the reconstituted peptide in the refrigerator.

Proper sterile technique is critical during reconstitution to maintain peptide integrity and prevent contamination. Bacteriostatic water for injection (BWFI) is commonly preferred for multi-dose vials.

• Weeks 1-2: Acute increase in GH levels will be observed shortly after injection. Some researchers note increased appetite and potentially improved sleep quality.
• Weeks 3-4: Initial subtle changes in body composition may begin, such as feeling 'tighter' or improved recovery post-exertion. Appetite stimulation often continues.
• Weeks 5-8: More noticeable improvements in body composition, including potential reductions in fat mass and increases in lean body mass, are commonly reported in research.
• Weeks 9-12: Peak benefits in body composition and recovery are typically observed. Consistent administration is key for sustained effects.
• Post-cycle: A return to baseline GH levels and a gradual reversal of some benefits may occur, depending on individual physiology and lifestyle factors.